IBDEI2MJ ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,44039,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44039,1,3,0)
 ;;=3^DM Type 2 w/ Circulatory Complications NEC
 ;;^UTILITY(U,$J,358.3,44039,1,4,0)
 ;;=4^E11.59
 ;;^UTILITY(U,$J,358.3,44039,2)
 ;;=^5002652
 ;;^UTILITY(U,$J,358.3,44040,0)
 ;;=E11.618^^200^2220^14
 ;;^UTILITY(U,$J,358.3,44040,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44040,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Arthropathy NEC
 ;;^UTILITY(U,$J,358.3,44040,1,4,0)
 ;;=4^E11.618
 ;;^UTILITY(U,$J,358.3,44040,2)
 ;;=^5002654
 ;;^UTILITY(U,$J,358.3,44041,0)
 ;;=E11.621^^200^2220^16
 ;;^UTILITY(U,$J,358.3,44041,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44041,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Foot Ulcer
 ;;^UTILITY(U,$J,358.3,44041,1,4,0)
 ;;=4^E11.621
 ;;^UTILITY(U,$J,358.3,44041,2)
 ;;=^5002656
 ;;^UTILITY(U,$J,358.3,44042,0)
 ;;=E11.622^^200^2220^20
 ;;^UTILITY(U,$J,358.3,44042,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44042,1,3,0)
 ;;=3^DM Type 2 w/ Skin Ulcer NEC
 ;;^UTILITY(U,$J,358.3,44042,1,4,0)
 ;;=4^E11.622
 ;;^UTILITY(U,$J,358.3,44042,2)
 ;;=^5002657
 ;;^UTILITY(U,$J,358.3,44043,0)
 ;;=E11.65^^200^2220^19
 ;;^UTILITY(U,$J,358.3,44043,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44043,1,3,0)
 ;;=3^DM Type 2 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,44043,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,44043,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,44044,0)
 ;;=E11.9^^200^2220^21
 ;;^UTILITY(U,$J,358.3,44044,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44044,1,3,0)
 ;;=3^DM Type 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,44044,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,44044,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,44045,0)
 ;;=E13.9^^200^2220^22
 ;;^UTILITY(U,$J,358.3,44045,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44045,1,3,0)
 ;;=3^Diabetes Mellitus (Secondary) w/o Complications NEC
 ;;^UTILITY(U,$J,358.3,44045,1,4,0)
 ;;=4^E13.9
 ;;^UTILITY(U,$J,358.3,44045,2)
 ;;=^5002704
 ;;^UTILITY(U,$J,358.3,44046,0)
 ;;=E16.2^^200^2220^29
 ;;^UTILITY(U,$J,358.3,44046,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44046,1,3,0)
 ;;=3^Hypoglycemia,Unspec
 ;;^UTILITY(U,$J,358.3,44046,1,4,0)
 ;;=4^E16.2
 ;;^UTILITY(U,$J,358.3,44046,2)
 ;;=^5002708
 ;;^UTILITY(U,$J,358.3,44047,0)
 ;;=E20.0^^200^2220^34
 ;;^UTILITY(U,$J,358.3,44047,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44047,1,3,0)
 ;;=3^Idiopathic Hypoparathyroidism
 ;;^UTILITY(U,$J,358.3,44047,1,4,0)
 ;;=4^E20.0
 ;;^UTILITY(U,$J,358.3,44047,2)
 ;;=^5002712
 ;;^UTILITY(U,$J,358.3,44048,0)
 ;;=E20.9^^200^2220^30
 ;;^UTILITY(U,$J,358.3,44048,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44048,1,3,0)
 ;;=3^Hypoparathyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,44048,1,4,0)
 ;;=4^E20.9
 ;;^UTILITY(U,$J,358.3,44048,2)
 ;;=^5002714
 ;;^UTILITY(U,$J,358.3,44049,0)
 ;;=E23.0^^200^2220^31
 ;;^UTILITY(U,$J,358.3,44049,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44049,1,3,0)
 ;;=3^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,44049,1,4,0)
 ;;=4^E23.0
 ;;^UTILITY(U,$J,358.3,44049,2)
 ;;=^60685
 ;;^UTILITY(U,$J,358.3,44050,0)
 ;;=E27.1^^200^2220^51
 ;;^UTILITY(U,$J,358.3,44050,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44050,1,3,0)
 ;;=3^Primary Adrenocortical Insufficiency
 ;;^UTILITY(U,$J,358.3,44050,1,4,0)
 ;;=4^E27.1
 ;;^UTILITY(U,$J,358.3,44050,2)
 ;;=^5002740
 ;;^UTILITY(U,$J,358.3,44051,0)
 ;;=E27.2^^200^2220^1
 ;;^UTILITY(U,$J,358.3,44051,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44051,1,3,0)
 ;;=3^Addisonian Crisis
 ;;^UTILITY(U,$J,358.3,44051,1,4,0)
 ;;=4^E27.2
 ;;^UTILITY(U,$J,358.3,44051,2)
 ;;=^263725
 ;;^UTILITY(U,$J,358.3,44052,0)
 ;;=E27.3^^200^2220^23
 ;;^UTILITY(U,$J,358.3,44052,1,0)
 ;;=^358.31IA^4^2
